Peptidase Inhibitors as a Possible Therapeutic Strategy for Chagas Disease

Current Enzyme Inhibition

Volumn 6, Issue 4, 2010, Pages 183-194

  Rodrigues, Giseli Capaci ^a   Aguiar, Alcino Palermo ^a   da Silva Gonçalves Vianez Jr , João Lídio ^b   Macrae, Andrew ^b   de Melo, Ana Cristina Nogueira ^b   Vermelho, Alane Beatriz ^b  

^a MILITARY INSTITUTE OF ENGINEERING   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

American trypanosomiasis; Chagas disease; Drug targets; Peptidase inhibitors; Peptidases; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; CRUZIPAIN; CYSTEINE PROTEINASE INHIBITOR; DIAZOMETHANE; ENZYME INHIBITOR; GELATINASE B; HALOMETHYL KETONE; HYDRAZONE DERIVATIVE; ISOXAZOLE DERIVATIVE; K 11002; K 11777; KETONE DERIVATIVE; METALLOPROTEINASE; N ACYLHYDRAZONE DERIVATIVE; N METHYLPIPERAZINE PHE HOMOPHE VINYLSULFONE PHENYL; OXADIAZOLE DERIVATIVE; PEPTIDASE INHIBITOR; PROLYL ENDOPEPTIDASE; PROLYLPROLYLISOXAZOLE DERIVATIVE; PROLYPROLYLISOXAZOLINE DERIVATIVE; PROTEINASE INHIBITOR; SULFONE DERIVATIVE; THIOSEMICARBAZONE DERIVATIVE; THREONINE; TRIAZINE DERIVATIVE; TRIAZINE NITRILE; TRIAZOLE; UNCLASSIFIED DRUG; VINYL SULFONE DERIVATIVE; WRR 483;

BIOSYNTHESIS; CHAGAS DISEASE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; HYPERTENSION; LIFE CYCLE; NEOPLASM; NONHUMAN; PARASITE; PATHOGENESIS; REVIEW; TRYPANOSOMA CRUZI;

TRYPANOSOMA CRUZI;

EID: 79954507305     PISSN: 15734080     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340810794578506     Document Type: Review

References (108)

1. Stuart, K.; Brun, R.; Croft, S.; Fairlamb, A.; Gürtler, R.E.; McKerrow, J.; Reed, S.; Tarleton, R. Kinetoplastids: related protozoan pathogens, different diseases. J. Clin. Invest., 2008, 118, 1301-1310.
2. Nóbrega, A.A.; Garcia, M.H.; Tatto, E.; Obara, M.T.; Costa, E.; Sobel, J.; Araujo W.N. Oral transmission of Chagas disease by consumption of açaí palm fruit, Brazil. Emerg. Infect. Dis., 2009, 15, 653-655.
3. Pereira, K.S.; Schmidt, F.L.; Guaraldo, A.M.; Franco, R.M.; Dias, V.L.; Passos, L.A. Chagas disease as a foodborne illness. J. Food Prot., 2009, 72, 441-446.
4. Rassi, A. Jr.; Rassi, A.; Marin-Neto, J.A. Chagas disease. Lancet, 2010, 375, 1388-1402.
5. Chagas, C. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem. Inst. Oswaldo Cruz, 1909, 1, 159-218.
6. Coura, J.R. Chagas disease: what is known and what is needed -A background article. Mem. Inst. Oswaldo Cruz., 2007, 102 (Suppl 1), 113-122.
7. Coura, J.R.; Dias, J.C. Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery. Mem. Inst. Oswaldo Cruz., 2009, 104 (Suppl 1), 31-40.
8. World Health Organization. Programmes and projects: Media centre: Fact sheets: Chagas disease. http://www.who.int/mediacentre/ factsheets/fs340/en/index.html (Accessed October 10, 2010).
9. Urbina, J.A.; Docampo, R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol., 2003, 19, 495-501.
10. Gobbi, P.; Presti, M.S.L.; Fernández, A.R.; Enders, J.E.; Fretes, R.; Gea, S.; Paglini-Oliva, P.A.; Rivarola, H.W. Allopurinol is effective to modify the evolution of Trypanosoma cruzi infection in mice. Parasitol. Res., 2007, 101, 1459-1462.
11. Soeiro, M.Z.C.; Castro, S.L. Trypanosoma cruzi targets for new chemotherapeutic approaches. Expert Opin. Ther. Targets, 2009, 13, 105-121.
12. Maya, J.D.; Cassels, B.K.; Iturriaga-Vásquez, P.; Ferreira, J.; Faúndez, M.; Galanti, N.; Ferreira, A.; Morello, A. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp. Biochem. Physiol. A Mol. Integr. Physiol., 2007, 146, 601-620.
13. Caldas, I.S.; Talvani, A.; Caldas, S.; Carneiro, C.M.; Lana, M.; Guedes, P.M.M.; Bahia, M.T. Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitol. Res., 2008, 103, 413-421.
14. Cavalli, A.; Lizzi, F.; Bongarzone, S.; Belluti, F.; Piazzi, L.; Bolognesi, M.L. Complementary medicinal chemistry-driven strategies toward new antitrypanosomal and antileishmanial lead drug candidates. FEMS Immunol. Med. Microbiol., 2010, 58, 51-60.
15. Filardi, L.S.; Brener, Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans. R. Soc. Trop. Med. Hyg., 1987, 81, 755-759.
16. Huang, L.; Lee, A.; Ellman, J.A. Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis. J. Med. Chem., 2002, 45, 676-684.
17. Andrade, H.M.; Murta, S.M.; Chapeaurouge, A.; Perales, J.; Nirdé, P.; Romanha, A.J. Proteomic analysis of Trypanosoma cruzi resistance to Benznidazole. J. Proteome Res., 2008, 7, 2357-2367.
18. Hartley, B.S. Proteolytic enzymes. Annu. Rev. Biochem., 1960, 29, 45-72.
19. Rawlings, N.D.; Barrett, A.J. Evolutionary families of peptidases. Biochem. J., 1993, 290, 205-218.
20. Turk, B.E.; Huang, L.L.; Piro, E.T.; Cantley, L.C. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat. Biotechnol., 2001, 19, 661-667.
21. Rawlings, N.D.; Tolle, D.P.; Barrett, A.J. Evolutionary families of peptidase inhibitors. Biochem. J., 2004, 378, 705-716.
22. Rawlings, N.D.; Barrett, A.J.; Bateman, A. MEROPS: the peptidase database. Nucleic Acids Res., 2010, 38, D227-D233.
23. Hoover, T.; Lippmann, M.; Grouzmann, E.; Marceau, F.; Herscu, P. Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors. Clin. Exp. Allergy, 2010, 40, 50-61.
24. Moyle, G.J.; Youle, M. Higgs, C.; Monaghan, J.; Prince, W.; Chapman, S.; Clendeninn, N.; Nelson, M.R. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. J. Clin. Pharmacol., 1998, 38, 736-743.
25. Hoekstra, R.; Eskens, FALM, Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist, 2001, 6, 415-427.
26. Franke de Cazzulo, B.M.; Martínez, J.; North, M.J.; Coombs, G.H.; Cazzulo, J.J. Effects of proteinase inhibitors on the growth and differentiation of Trypanosoma cruzi. FEMS Microbiol. Lett., 1994, 124, 81-86.
27. McKerrow, J.M.; Rosenthal, P.J.; Swenerton, R.; Doyle, P. Development of protease inhibitors for protozoan infections. Curr. Opin. Infect. Dis., 2008, 21, 668-672.
28. Vermelho, A.B.; De Simone, S.G.; d'Avila-Levy, C.M.; Santos, A.L.S.; Melo, A.C.N.; Silva Jr., F.P.; Bon, E.P.S; Branquinha, M.H. Trypanosomatidae peptidases: a target for drugs development. Curr. Enzyme Inhib., 2007, 3, 19-48.
29. Coura, J.R. Present situation and new strategies for Chagas disease chemotherapy -a proposal. Mem. Inst. Oswaldo Cruz, 2009, 104, 549-554.
30. Cazzulo, J.J. Proteinases of Trypanosoma cruzi: potential targets for the chemotherapy of Chagas disease. Curr. Top. Med. Chem., 2002, 2, 1261-1271.
31. Duschak, V.G.; Couto, A.S. Cruzipain, the major cysteine protease of Trypanosoma cruzi: a sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. A review. Curr. Med. Chem., 2009, 16, 3174-3202.
32. Vermelho, A.B.; Branquinha, M.H.; D'Avila-Levy, C.M.; Santos, A.L.S.; Dias, E.P.S.; Nogueira de Melo, A.C. Biological roles of peptidases in Trypanosomatids. Open Parasitol. J., 2010, 4, 5-23.
33. Murta, A.C.; Persechini, P.M.; Padron, T.S.; de Souza, W.; Guimarães, J.A.; Scharfstein, J. Structural and functional identification of GP57/51 antigen of Trypanosoma cruzi as a cysteine proteinase. Mol. Biochem. Parasitol., 1990, 43, 27-38.
34. Eakin, A.E.; Mills, A.A.; Harth, G.; McKerrow, J.H.; Craik, C.S. The sequence, organization, and expression of the major cysteine proteinase (cruzain) from Trypanosoma cruzi. J. Biol. Chem., 1992, 267, 7411-7420.
35. Cazzulo, J.J.; Stoka, V.; Turk, V. The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease. Curr. Pharm. Des., 2001, 7, 1143-1156.
36. Mottram, J.C.; Helms, M.J.; Coombs, G.H.; Sajid, M. Clan CD cysteine peptidases of parasitic protozoa. Trends Parasitol., 2003, 19, 182-187.
37. Cazzulo, J.J.; Couso, R.; Raimondi, A.; Wernstedt, C.; Hellman, U. Further characterization and partial amino acid sequence of a cysteine proteinase from Trypanosoma cruzi. Mol. Biochem. Parasitol., 1989, 33, 33-41.
38. Paiva, C.N.; Souto-Padrón, T.; Costa, D.A.; Gattass, C.R. High expression of a functional cruzipain by a non-infective and nonpathogenic Trypanosoma cruzi clone. Parasitology, 1998, 117, 483-490.
39. Villalta, F.; Scharfstein, J.; Ashton, A.W, Tyler, K.M.; Guan, F.; Mukherjee, S.; Lima, M.F.; Alvarez, S.; Weiss, L.M.; Huang, H.; Machado, F.S.; Tanowitz, H.B. Perspectives on the Trypanosoma cruzi-host cell receptor interactions. Parasitol. Res., 2009, 104, 1251-1260.
40. Costales, J.; Rowland, E.C. A role for protease activity and hostcell permeability during the process of Trypanosoma cruzi egress from infected cells. J. Parasitol., 2007, 93, 1350-1359.
41. Nogueira de Melo, A.C.; de Souza, E.P.; Elias, C.G.; dos Santos, A.L.; Branquinha, M.H.; d'Ávila-Levy, C.M.; dos Reis, F.C.; Costa, T.F.; de Araujo Lima, A.P.; de Souza Pereira, M.C.; Meirelles, M.N.; Vermelho, A.B. Detection of matrix metallopeptidase-9-like proteins in Trypanosoma cruzi. Exp. Parasitol., 2010, 125, 256-263.
42. Del Nery, E.; Juliano, M.A.; Lima, A.P.C.A.; Scharfstein, J.; Juliano, L. Kininogenase activity by major cysteinyl proteinase (Cruzipain) from Trypanosoma cruzi. J. Biol. Chem., 1997, 272, 25713-25718.
43. Scharfstein, J.; Schmitz, V.; Morandi, V.; Capella, M.M.; Lima, A.P.; Morrot, A.; Juliano, L.; Muller-Esterl, W. Host cell invasion by Trypanosoma cruzi is potentiated by activation of bradykinin B(2) receptors. J. Exp. Med., 2000, 192, 1289-1300.
44. Benítez-Hernández, I.; Méndez-Enríquez, E.; Ostoa, P.; Fortoul, T.; Ramírez, J.A.; Stempin, C.; Cerbán, F.; Soldevila, G.; García-Zepeda, E.A. Proteolytic cleavage of chemokines by Trypanosoma cruzi's cruzipain inhibits chemokine functions by promoting the generation of antagonists. Immunobiology, 2010, 215, 413-426.
45. Garcia, M.P.; Nóbrega, O.T.; Teixeira, A.R.; Sousa, M.V.; Santana, J.M. Characterisation of a Trypanosoma cruzi acidic 30 kDa cysteine protease. Mol. Biochem. Parasitol., 1998, 91, 263-272.
46. Yong, V.; Schmitz, V.; Vannier-Santos, M.A.; de Lima, A.P.; Lalmanach, G.; Juliano, L.; Gauthier, F.; Scharfstein, J. Altered expression of cruzipain and a cathepsin B-like target in a Trypanosoma cruzi cell line displaying resistance to synthetic inhibitors of cysteine-proteinases. Mol. Biochem. Parasitol., 2000, 109, 47-59.
47. Duschak, V.G.; Barboza, M.; García, G.A.; Lammel, E.M.; Couto, A.S.; Isola, E.L.D. Novel cysteine proteinase in Trypanosoma cruzi metacyclogenesis. Parasitology, 2006, 132, 345-355.
48. Brak, K.; Doyle, P.S.; McKerrow, J.H.; Ellman, J.A. Identification of a new class of nonpeptidic inhibitors of cruzain. J. Am. Chem. Soc., 2008, 130, 6404-6410.
49. Engel, J.C.; Doyle, P.S.; Palmer, J.; Hsieh, I.; Bainton, D.F.; McKerrow, J.H. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J. Cell. Sci., 1998, 111, 597-606.
50. Engel, J.C.; Doyle, P.S.; McKerrow, J.H. Trypanocidal effect of cysteine protease inhibitors in vitro and in vivo in experimental Chagas disease. Medicina, 1999, 59 (Suppl II), 171-175.
51. Caffrey, C.R.; Scory, S.; Steverding, D. Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy. Curr. Drug Targets, 2000, 1, 155-162.
52. McKerrow, J.H.; Doyle, P.S.; Engel, J.C.; Podust, L.M.; Robertson, S.A.; Ferreira, R.; Saxton, T.; Arkin, M.; Kerr, I.D.; Brinen, L.S.; Craik, C.S. Two approaches to discovering and developing new drugs for Chagas disease. Mem. Inst. Oswaldo Cruz, 2009, 104 (Suppl. I), 263-269.
53. Cazzulo, J.J.; Stoka, V.; Turk, V. Cruzipain, the major cysteine proteinase from the protozoan parasite Trypanosoma cruzi. Biol. Chem., 1997, 378, 1-10.
54. Duschak, V.G.; Couto, A.S. An insight on targets and patented drugs for chemotherapy of Chagas disease. Recent Pat. Antiinfect. Drug Discov., 2007, 2, 19-51.
55. McGrath, M.E.; Eakin, A.E.; Engel, J.C.; McKerrow, J.H.; Craik, C.S.; Fletterick, R.J. The crystal structure of cruzain: a therapeutic target for Chagas' disease. J. Mol. Biol., 1995, 247, 251-259.
56. Brinen, L.S.; Hansell, E.; Cheng, J.; Roush, W.R.; McKerrow, J.H.; Fletterick, R.J. A target within the target: probing cruzain's P1' site to define structural determinants for the Chagas' disease protease. Structure, 2000, 8, 831-840.
57. McKerrow, J.H.; McGrath, M.E.; Engel, J.C. The cysteine protease of Trypanosoma cruzi as a model for antiparasite drug design. Parasitol. Today, 1995, 11, 279-282.
58. McKerrow, J.H.; Engel, J.C.; Caffrey, C.R. Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg. Med. Chem., 1999, 7, 639-644.
59. Mallari, J.P.; Shelat, A.A.; Obrien, T. Caffrey, C.R.; Kosinski, A.; Connelly, M.; Harbut, M.; Greenbaum, D.; McKerrow, J.H.; Guy, R.K. Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. J. Med. Chem., 2008, 51, 545-552.
60. Durrant, J.D.; Keränen, H.; Wilson, B.A.; McCammon, J.A. Computational identification of uncharacterized cruzain binding sites. PLoS Negl. Trop. Dis., 2010, 4, e676.
61. Powers, J.C.; Asgian, J.L.; Ekici, O.D.; James, K.E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev., 2002, 102, 4639-4750.
62. Ashall, F.; Angliker, H.; Shaw, E. Lysis of trypanosomes by peptidyl fluoromethyl ketones. Biochem. Biophys. Res. Commun., 1990, 170, 923-929.
63. Harth, G.; Andrews, N.; Mills, A.A.; Engel, J.C.; Smith, R.; McKerrow, J.H. Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi. Mol. Biochem. Parasitol., 1993, 58, 17-24.
64. Du, X.; Guo, C.; Hansell, E.; Doyle, P.S.; Caffrey, C.R.; Holler, T.P.; McKerrow, J.H.; Cohen, F.E. Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J. Med. Chem., 2002, 45, 2695-2707.
65. Shaw, E. Peptidyl diazomethanes as inhibitors of cysteine and serine proteinases. Methods Enzymol., 1994, 244, 649-656.
66. Lalmanach, G.; Mayer, R.; Serveau, C.; Scharfstein, J.; Gauthier, F. Biotin-labelled peptidyl diazomethane inhibitors derived from the substrate like sequence of cystatin: targeting of the active site of cruzipain, the major cysteine proteinase of Trypanosoma cruzi. Biochem. J., 1996, 318, 395-399.
67. Rasnick, D. Synthesis of Peptide fluoromethyl ketones and the inhibition of human cathepsin B. Anal. Biochem., 1985, 149, 461-465.
68. Palmer, J.T.; Rasnick, D.; Klaus, J.L.; Bromme, D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem., 1995, 38, 3193-3196.
69. Roush, W.R.; Cheng, J.; Knapp-Reed, B.; Alvarez-Hernandez, A.; McKerrow, J.H.; Hansell, E.; Engel, J.C. Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain. Bioorg. Med. Chem. Lett., 2001, 11, 2759-2762.
70. Engel, J.C.; Doyle, P.S.; Hsieh, I.; Mckerrow, J.H. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med., 1998, 188, 725-734.
71. Barr, S.C.; Warner, K.L.; Kornreic, B.G.; Piscitelli, J.; Wolfe, A.; Benet, L.; McKerrow, J.H. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob. Agents Chemother., 2005, 49, 5160-5161.
72. Kerr, I.D.; Lee, J.H.; Farady, C.J.; Marion, R.; Rickert, M.; Sajid, M.; Pandey, K.C.; Caffrey, C.R.; Legac, J.; Hansell, E.; McKerrow, J.H.; Craik, C.S.; Rosenthal, P.J.; Brinen, L.S. Vinyl sulfones as antiparasitic agents and a structural basis for drug design. J. Biol. Chem., 2009, 284, 25697-25703.
73. Jacobsen, W.; Christians, U.; Benet, L. Z. In vitro evaluation of the disposition of a novel cysteine protease inhibitor. Drug Metab. Dispos., 2000, 28, 1343-1351.
74. Chen, Y.T.; Brinen, L.S.; Kerr, I.D.; Hansell, E.; Doyle, P.S.; McKerrow, J.H.; Roush, W.R. In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi. PLoS Negl. Trop. Dis., 2010, 4, e825.
75. Ifa, D.R.; Rodrigues, C.R.; de Alencastro, R.B.; Fraga, C.A.M.; Barreiro, E.J. A possible molecular mechanism for the inhibition of cysteine proteases by salicylaldehyde N-acylhydrazones and related compounds. J. Mol. Struct. (Theochem), 2000, 505, 11-17.
76. Ribeiro, I.G.; da Silva, K.C.M.; Parrini, S.C.; Miranda, A.P.; Fraga, C.A.M.; Barreiro E.J. Synthesis and antinociceptive properties of new structurally planned imidazo [1,2-a]pyridine 3-acylarylhydrazone derivatives. Eur. J. Med. Chem., 1998, 33, 225-235.
77. Lima, L.M.; Romeiro, N.C.; Aguirre, G.; Hernández, P.; González, M.; Cerecetto, H.; Aldana, I.; Pérez-Silanes, S.; Monge, A.; Barreiro, E.J. Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorg. Med. Chem., 2009, 17, 641-652.
78. dos Santos Filho, J.M.; Lima Leite, A.C.; de Oliveira, B.G.; Magalhães Moreira, D.G.; Lima, M.S.; Botelho Pereira Soares, M.; Leite, L.F.C.C. Design, synthesis and cruzain docking of 3-(4-substituted-aryl)-1,2,4-oxadiazole-N-acylhydrazones as anti-Trypanosoma cruzi agents. Bioorg. Med. Chem., 2009, 17, 6682-6691.
79. McKerrow, J.H. Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. Int. J. Parasitol., 1999, 29, 833-837.
80. Du, X.; Hansell, E.; Engel, J.C.; Caffrey, C.R.; Cohen, F.E.; McKerrow, J.H. Aryl ureas represent a new class of antitrypanosomal agents. Chem. Biol., 2000, 7, 733-742.
81. Ferreira, R.S.; Bryant, C.; Ang, K.K.; McKerrow, J.H.; Shoichet, B.K.; Renslo, A.R. Divergent modes of enzyme inhibition in a homologous structure-activity series. J. Med. Chem., 2009, 52, 5005-5008.
82. Bryant, C.; Kerr, I.D.; Debnath, M.; Ang, K.K.; Ratnam, J.; Ferreira, R.S.; Jaishankar, P.; Zhao, D.; Arkin, M.R.; McKerrow, J.H.; Brinen, L.S.; Renslo, A.R. Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases. Bioorg. Med. Chem. Lett., 2009, 19, 6218-6221.
83. Brak, K.; Kerr, I.D.; Barrett, K.T.; Fuchi, N.; Debnath, M.; Ang, K.; Engel, J.C.; McKerrow, J.H.; Doyle, P.S.; Brinen, L.S.; Ellman, J.A. Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy. J. Med. Chem., 2010, 53, 1763-1773.
84. Mott, B.T.; Ferreira, R.S.; Simeonov, A.; Jadhav, A.; Ang, K.K.; Leister, W.; Shen, M.; Silveira, J.T.; Doyle, P.S.; Arkin, M.R.; McKerrow, J.H.; Inglese, J.; Austin, C.P.; Thomas, C.J.; Shoichet, B.K.; Maloney, D.J. Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB. J. Med. Chem., 2010, 53, 52-60.
85. Trott, O.; Olson, A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput. Chem., 2010, 31, 455-461.
86. 2+-signaling factor for mammalian cells. J. Biol. Chem., 1995, 270, 5172-5180.
87. 2+ signaling in mammalian cells. J. Cell. Biol., 1997, 136, 609-620.
88. Caler, E.V.; Avalos, V.; Haynes, P.A.; Andrews, N.W.; Burleigh, B.A. Oligopeptidase B-dependent signaling mediates host cell invasion by Trypanosoma cruzi. EMBO J., 1998, 17, 4975-4986.
89. Grellier, P.; Vendeville, S.; Joyeau, R.; Bastos, I.M.; Drobecq, H.; Frappier, F.; Teixeira, A.R.; Schrével, J.; Davioud-Charvet, E.; Sergheraert, C.; Santana, J.M. Trypanosoma cruzi prolyl oligopeptidase Tc80 is involved in nonphagocytic mammalian cell invasion by trypomastigotes. J. Biol. Chem., 2001, 276, 47078-47086.
90. Bastos, I.M.; Grellier, P.; Martins, N.F.; Cadavid-Restrepo, G.; de Souza-Ault, M.R.; Augustyns, K.; Teixeira, A.R.; Schrével, J.; Maigret, B.; da Silveira, J.F.; Santana, J.M. Molecular, functional and structural properties of the prolyl oligopeptidase of Trypanosoma cruzi (POP Tc80), which is required for parasite entry into mammalian cells. Biochem. J., 2005, 15, 29-38.
91. da Silva-Lopez, R.E.; Morgado-Díaz, J.A.; dos Santos, P.T.; Giovanni-De-Simone, S. Purification and subcellular localization of a secreted 75 kDa Trypanosoma cruzi serine oligopeptidase. Acta Trop., 2008, 107, 159-167.
92. Bal, G.; Van der Veken, P.; Antonov, D.; Lambeir, A.M.; Grellier, P.; Croft, S.L.; Augustyns, K.; Haemers, A. Prolylisoxazoles: potent inhibitors of prolyloligopeptidase with antitrypanosomal activity. Bioorg. Med. Chem. Lett., 2003, 13, 2875-2878.
93. Vendeville, S.; Bourel, L.; Davioud-Charvet, E.; Grellier, P.; Deprez, B.; Sergheraert, C. Automated parallel synthesis of a tetrahydroisoquinolin-based library: potential prolyl endopeptidase inhibitors. Bioorg. Med. Chem. Lett., 1999, 9, 437-442.
94. Vendeville, S.; Goossens, F.; Debreu-Fontaine, M.A.; Landry, V.; Davioud-Charvet, E.; Grellier, P.; Scharpe, S.; Sergheraert, C. Comparison of the inhibition of human and Trypanosoma cruzi prolyl endopeptidases. Bioorg. Med. Chem., 2002, 10, 1719-1729.
95. Tsutsumi, S.; Okonogi, T.; Shibahara, S.; Ohuchi, S.; Hatsushiba, E.; Patchett, A.A.; Christensen, B.G. Synthesis and structureactivity relationships of peptidyl alpha-keto heterocycles as novel inhibitors of prolyl endopeptidase. J. Med. Chem., 1994, 37, 3492-3502.
96. Bonaldo, M.C.; d'Escoffier, L.N.; Salles, J.M.; Goldenberg, S. Characterization and expression of proteases during Trypanosoma cruzi metacyclogenesis. Exp. Parasitol., 1991, 73, 44-51.
97. Lowndes, C.M.; Bonaldo, M.C.; Thomaz, N.; Goldenberg, S. Heterogeneity of metalloprotease expression in Trypanosoma cruzi. Parasitology, 1996, 112, 393-399.
98. Cuevas, I.C.; Cazzulo, J.J.; Sanchez, D.O. gp63 homologues in Trypanosoma cruzi: surface antigens with metalloprotease activity and a possible role in the host cell infection. Infect. Immun., 2003, 71, 5739-5749.
99. Kulkarni, M.M.; Olson, C.L.; Engman, D.M.; McGwire, B.S. Trypanosoma cruzi GP63 proteins undergo stage-specific differential posttranslational modification and are important for host cell infection. Infect. Immun., 2009, 77, 2193-2200.
100. Gutierrez, F.R.; Lalu, M.M.; Mariano, F.S.; Milanezi, C.M.; Cena, J.; Gerlach, R.F.; Santos, J.E.; Torres-Dueñas, D.; Cunha, F.Q.; Schulz, R.; Silva, J.S. Increased activities of cardiac matrix metal loproteinases matrix metalloproteinase (MMP)-2 and MMP-9 are associated with mortality during the acute phase of experimental Trypanosoma cruzi infection. J. Infect. Dis., 2008, 197, 1468-1476.
101. Nogueira de Melo, A.C.; Meirelles, M.N.L.; Porrozzi, R.; Costa, J.D.; Branquinha, M.H.; Vermelho, A.B. Reduced activity of matrix metalloproteinase-9 in Trypanosoma cruzi infected mouse embryo hepatocyte cell. Hepatol. Res., 2004, 28, 49-56.
102. Burleigh, B.A.; Woolsey, A.M. Cell signaling and Trypanosoma cruzi invasion. Cell. Microbiol., 2002, 4, 701-711.
103. Niemirowicz, G.; Parusini, F.; Aguero, F.; Cazulo, J.J. Two metallocarboxipeptidases from the protozoan Trypanosoma cruzi belong to the M32 family, found so far only in prokaryotes. Biochem. J., 2007, 401, 399-410.
104. Niemirowicz, G.; Fernández, D.; Solà, M.; Cazzulo, J.J.; Avilés, F.X.; Gomis-Rüth, F.X. The molecular analysis of Trypanosoma cruzi metallocarboxypeptidase 1 provides insight into fold and substrate specificity. Mol. Microbiol., 2008, 70, 853-866.
105. Pinho, R.T.; Beltramini, L.M.; Alves, C.R.; De-Simone, S.G. Trypanosoma cruzi: isolation and characterization of aspartyl proteases. Exp. Parasitol., 2009, 122, 128-133.
106. Nkemgu-Njinkeng, J.; Rosenkranz, V.; Wink, M.; Steverding, D. Antitrypanosomal activities of proteasome inhibitors. Antimicrob. Agents Chemother., 2002; 46, 2038-2040.
107. Cardoso, J.; Soares, M.J.; Menna-Barreto, R.F.S.; Le Bloas, R.; Sotomaior, V.; Goldenberg, S.; Krieger, M.A. Inhibition of proteasome activity blocks Trypanosoma cruzi growth and metacyclogenesis. Parasitol. Res., 2008, 103, 941-951.
108. Gutiérrez, B.; Osorio, L.; Motta, M.C.; Huima-Byron, T.; Erdjument-Bromage, H.; Muñoz, C.; Sagua, H.; Mortara, R.A.; Echeverría, A.; Araya, J.E.; González, J. Molecular characterization and intracellular distribution of the alpha 5 subunit of Trypanosoma cruzi 20S proteasome. Parasitol. Int., 2009, 58, 367-374.